| 000 | 01742 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250517095740.0 | ||
| 264 | 0 | _c20170911 | |
| 008 | 201709s 0 0 eng d | ||
| 022 | _a1179-1926 | ||
| 024 | 7 |
_a10.1007/s40262-016-0412-5 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBudha, Nageshwar R | |
| 245 | 0 | 0 |
_aEvaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation. _h[electronic resource] |
| 260 |
_bClinical pharmacokinetics _c11 2016 |
||
| 300 |
_a1435-1445 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAlkynes |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 |
_aAzetidines _xpharmacokinetics |
| 650 | 0 | 4 |
_aBenzoxazines _xpharmacology |
| 650 | 0 | 4 | _aComputer Simulation |
| 650 | 0 | 4 | _aCyclopropanes |
| 650 | 0 | 4 |
_aCytochrome P-450 CYP3A _xmetabolism |
| 650 | 0 | 4 |
_aCytochrome P-450 CYP3A Inducers _xpharmacology |
| 650 | 0 | 4 |
_aCytochrome P-450 CYP3A Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aDiltiazem _xpharmacology |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 |
_aErythromycin _xpharmacology |
| 650 | 0 | 4 |
_aFluvoxamine _xpharmacology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aModels, Biological |
| 650 | 0 | 4 |
_aPiperidines _xpharmacokinetics |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 |
_aRifampin _xpharmacology |
| 700 | 1 | _aJi, Tao | |
| 700 | 1 | _aMusib, Luna | |
| 700 | 1 | _aEppler, Steve | |
| 700 | 1 | _aDresser, Mark | |
| 700 | 1 | _aChen, Yuan | |
| 700 | 1 | _aJin, Jin Y | |
| 773 | 0 |
_tClinical pharmacokinetics _gvol. 55 _gno. 11 _gp. 1435-1445 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s40262-016-0412-5 _zAvailable from publisher's website |
| 999 |
_c26060175 _d26060175 |
||